Nisa Investment Advisors LLC Buys 22,425 Shares of Illumina, Inc. (NASDAQ:ILMN)

Nisa Investment Advisors LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 238.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,844 shares of the life sciences company's stock after acquiring an additional 22,425 shares during the quarter. Nisa Investment Advisors LLC's holdings in Illumina were worth $4,434,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ILMN. Acadian Asset Management LLC increased its position in Illumina by 312.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company's stock valued at $702,000 after acquiring an additional 1,525 shares during the period. Dimensional Fund Advisors LP boosted its stake in Illumina by 3.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company's stock valued at $82,853,000 after purchasing an additional 7,114 shares in the last quarter. Dakota Wealth Management boosted its stake in Illumina by 13.8% during the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company's stock valued at $288,000 after purchasing an additional 100 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in Illumina by 16.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company's stock valued at $281,000 after purchasing an additional 116 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its stake in Illumina by 10.2% during the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company's stock valued at $17,108,000 after purchasing an additional 4,548 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 2.8 %

Shares of Illumina stock traded down $3.63 during midday trading on Friday, hitting $127.07. The company's stock had a trading volume of 1,629,451 shares, compared to its average volume of 1,764,596. The firm has a market capitalization of $20.24 billion, a P/E ratio of -17.31 and a beta of 1.19. The stock has a 50-day simple moving average of $135.77 and a 200-day simple moving average of $128.47. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $232.88.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.09 billion. During the same quarter last year, the firm posted $0.14 earnings per share. Illumina's revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Jacob Thaysen acquired 7,330 shares of the business's stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. StockNews.com raised Illumina from a "hold" rating to a "buy" rating in a research note on Friday, February 16th. Stephens reaffirmed an "overweight" rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday. HSBC lowered Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. TD Cowen lowered Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 price objective for the company. in a research note on Thursday, January 4th. Finally, Sanford C. Bernstein raised Illumina from an "underperform" rating to a "market perform" rating in a research note on Friday, December 15th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.